First Reported Case of Ocrelizumab-Associated Leukocytoclastic Vasculitis in Primary Progressive Multiple Sclerosis: A Case Report.

Fatemeh Khosravani

doi:10.1159/000548629

December 1, 2025

First Reported Case of Ocrelizumab-Associated Leukocytoclastic Vasculitis in Primary Progressive Multiple Sclerosis: A Case Report.

View Full Paper

Ask AI

Bookmark

Share

Key Points

Ocrelizumab treatment led to leukocytoclastic vasculitis in a patient.
The patient experienced symptoms linked to vasculitis after therapy initiation.
Observational case report further explores drug-related adverse effects on immune-modulating treatments.
Clinical awareness of ocrelizumab's potential to cause vasculitis is crucial for patient safety.

Implication

Case report identifies leukocytoclastic vasculitis in multiple sclerosis, suggesting drug therapy may lead to serious adverse effects.

Abstract

This case is the first reported instance of LCV associated with ocrelizumab in the treatment of multiple sclerosis. It underscores the need for awareness of potential drug-induced vasculitis in patients undergoing new or modified treatments and contributes to the growing understanding of adverse effects associated with ocrelizumab.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fatemeh Khosravani (2025) studied this question.

synapsesocial.com/papers/69337cdbb3f947a0a1259eee https://doi.org/10.1159/000548629

View Full Paper

Ask AI

Bookmark

Share

First Reported Case of Ocrelizumab-Associated Leukocytoclastic Vasculitis in Primary Progressive Multiple Sclerosis: A Case Report.

Key Points

Implication

Abstract

Discussion

Cite This Study

First Reported Case of Ocrelizumab-Associated Leukocytoclastic Vasculitis in Primary Progressive Multiple Sclerosis: A Case Report.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading